This site is intended for healthcare professionals

FDA issues a Complete Response Letter relating to the BLA for PRX 102 for the proposed treatment of Fabry disease.- Protalix BioTherapeutics,

Read time: 1 mins
Last updated:30th Apr 2021
Published:30th Apr 2021
Condition: Fabry Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest